CDK4 and lung cancer: Interestingly, it has been found to affect cell growth of leukemic cells via CDK4/6 inhibition [28] and PI3K/AKT/mTOR signaling pathway disruption [29,30], while in lung cancer cells, fascaplysin-induced cell death is independent from the presence and activity of CDK4, suggesting that other molecular targets are involved [29].